FORM 3
        	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
	OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5	
                      	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	                      	

1. Name and Address of Reporting Person *

Dahowski Diane	2. Date of Event Requiring Statement (MM/DD/YYYY)
4/27/2022 
	3. Issuer Name and Ticker or Trading Symbol

BIO-RAD LABORATORIES, INC. [BIO BIOB]	
(Last)        (First)        (Middle)

C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE	4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
EVP, Global Supply Chain /	
(Street)

HERCULES, CA 94547      

(City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)
 
	6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned	
1.Title of Security
(Instr. 4)	2. Amount of Securities Beneficially Owned
(Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)	4. Nature of Indirect Beneficial Ownership
(Instr. 5)	
Bio-Rad A Common Stock 	9007.9640 	D 	 	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)	
1. Title of Derivate Security
(Instr. 4)	2. Date Exercisable and Expiration Date
(MM/DD/YYYY)	3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)	6. Nature of Indirect Beneficial Ownership
(Instr. 5)	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units 	 (1)	 (1)	Bio-Rad A Common Stock 	600 	$0 (6)	D 	 	
Restricted Stock Units 	 (2)	 (2)	Bio-Rad A Common Stock 	1200 	$0 (6)	D 	 	
Restricted Stock Units 	 (3)	 (3)	Bio-Rad A Common Stock 	1485 	$0 (6)	D 	 	
Restricted Stock Units 	 (4)	 (4)	Bio-Rad A Common Stock 	1083 	$0 (6)	D 	 	
Restricted Stock Units 	 (5)	 (5)	Bio-Rad A Common Stock 	1317 	$0 (6)	D 	 	
Non-Qualified Stock Option (right to buy) 	 (7)	9/2/2030 	Bio-Rad A Common Stock 	1444 	$524.30 	D 	 	
Non-Qualified Stock Option (right to buy) 	 (8)	9/1/2031 	Bio-Rad A Common Stock 	1317 	$814.95 	D 	 	

Explanation of Responses:	
(1) 	On September 5, 2017, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.	
(2) 	On September 4, 2018, the reporting person was granted 3,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.	
(3) 	On September 3, 2019, the reporting person was granted 2,475 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date.	
(4) 	On September 2, 2020, the reporting person was granted 1,444 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.	
(5) 	On September 1, 2021, the reporting person was granted 1,317 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.	
(6) 	Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.	
(7) 	The option, representing a right to purchase a total of 1,444 shares, becomes exercisable in four equal annual installments beginning on September 2, 2021, which is the first anniversary of the date on which the option was granted.	
(8) 	The option, representing a right to purchase a total of 1,317 shares, becomes exercisable in four equal annual installments beginning on September 1, 2022, which is the first anniversary of the date on which the option was granted.	

Reporting Owners	
Reporting Owner Name / Address	Relationships	
	Director	10% Owner	Officer	Other	
Dahowski Diane
C/O BIO-RAD LABORATORIES, INC.
1000 ALFRED NOBEL DRIVE
HERCULES, CA 94547			EVP, Global Supply Chain		

Signatures		
/s/ Diane Dahowski		5/6/2022	
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).	
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.